Myriad GeneticsSTU:MYD -1.68%53 Gross Margin % is 68.66% as of Mar. 2026, which is 3% below its 10-year median of 71.13. GuruFocus rates STU:MYD with a GF Score™ of 53/100 and a GF Value™ of €13.15 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Myriad Genetics ranks better than 75.26% on this metric.
The historical rank and industry rank for Myriad Genetics's Gross Margin % or its related term are showing as below:
STU:MYD'
s Gross Margin % Range Over the Past 10 Years
Min: 68.64 Med: 71.13 Max: 78.76
Current: 69.96
During the past 13 years, the highestGross Margin % of Myriad Genetics was 78.76%. The lowest was 68.64%. And the median was 71.13%.
STU:MYD's Gross Margin % is ranked better than 75.26% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.45
vs STU:MYD: 69.96
Myriad Genetics had a gross margin of 68.66% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Myriad Genetics was -0.40% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Myriad Genetics had a gross margin of 68.66% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Myriad Genetics Gross Margin % Related Terms
Myriad Genetics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Myriad Genetics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MYD vs FLGT, CSTL, BDSX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Myriad Genetics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Myriad Genetics (STU:MYD) has a Gross Margin % of 68.66% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Myriad Genetics and its competitors. This is near median its historical median of 71.13. Over the past decade, Myriad Genetics' Gross Margin % has ranged from 68.64 to 78.76. According to the industry distribution chart, Myriad Genetics ranks #48 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 24.7%.
Is Myriad Genetics' Gross Margin % too high?
Myriad Genetics' current Gross Margin % of 68.66% is near median its 10-year median of 71.13. Over the past 10 years, this metric has ranged from a low of 68.64 to a high of 78.76. The Medical Diagnostics & Research industry median Gross Margin % is 50.45. Myriad Genetics' value of 68.66% is 36.1% above this industry median. Based on the distribution chart, Myriad Genetics ranks #48 out of 194 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Myriad Genetics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Gross Margin % compare to FLGT and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #48 out of 194 companies for Gross Margin %. This places Myriad Genetics in the top 25% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 50.45. Myriad Genetics' value of 68.66% is 36.1% above this benchmark. Historically, Myriad Genetics' own Gross Margin % has ranged from 68.64 to 78.76 over the past decade. While the company's 10-year median is 71.13 vs. the industry median of 50.45, Myriad Genetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.45, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Myriad Genetics's current Gross Margin % of 68.66% is 36.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Myriad Genetics and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myriad Genetics's current Gross Margin % is 68.66%, which is near median its own 10-year median of 71.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €13.15, compared to a current price of €4.96 — trading 62.3% below its estimated fair value. The current Gross Margin % is 68.66%, which is near median its 10-year median of 71.13 and 36.1% above the Medical Diagnostics & Research industry median of 50.45. Myriad Genetics' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current Gross Margin % is 68.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (STU:MYD) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of €4.96 is trading 62.3% below its estimated GF Value™ of €13.15.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for STU:MYD:
Gross Margin %: 68.66% (near median its 10-year median of 71.13)
GF Value™: €13.15 vs. price of €4.96 (62.3% below fair value)
Industry Position: 36.1% above the Medical Diagnostics & Research median (#48 of 194)
No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
53GF Score
Get the complete analysis for STU:MYD
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MYD has been successfully added to your 
